Table 2.
Biomarker panels improving the specificity of AG PCa detection
| AUC (95% CI) | SN (%) | SP (%) (p-value*) | True-Neg | True-Pos | False-Neg | False-Pos | |
|---|---|---|---|---|---|---|---|
| AG vs Low Risk PCa | |||||||
| Panel-1 | 0.942 (0.876-1.000) | 95.0 | 76.0 (0.029) | 19 | 24 | 1 | 6 |
| phi + Fuc-PSA | 0.914 (0.828-0.980) | 95.0 | 76.0 (0.013) | 19 | 24 | 1 | 6 |
| phi | 0.872 (0.748-0.971) | 95.0 | 56.0 | 14 | 24 | 1 | 11 |
| PSA | 0.866 (0.749-0.956) | 95.0 | 44.0 | 11 | 24 | 1 | 14 |
| AG vs Low Risk PCa & Non-PCa | |||||||
| Panel-2 | 0.934 (0.866-0.987) | 95.0 | 78.2 (0.010) | 43 | 24 | 1 | 12 |
| phi + Fuc-PSA | 0.918 (0.842-0.974) | 95.0 | 69.1 (0.207) | 38 | 24 | 1 | 17 |
| phi | 0.898 (0.814-0.963) | 95.0 | 65.5 | 36 | 24 | 1 | 19 |
| PSA | 0.807 (0.697-0.905) | 95.0 | 36.4 | 20 | 24 | 1 | 35 |
Note: PCa, prostate cancer; AG, aggressive PCa; Non-PCa, biopsy negative; Panel-1, phi + Fuc-PSA + SDC1 + GDF-15; Panel-2, phi + Fuc-PSA + SDC1 + Tie-2; AUC, area under curve; CI, confidence interval; SN, sensitivity; SP, specificity; Neg, negative; Pos, positive. *, one-sided paired test comparing specificity against phi.